Why the study?
Does apoA-I measurement improve the prediction of heart disease and myocardial infarction compared to HDL-C?
Does apoA-I measurement improve the prediction of heart disease and myocardial infarction compared to HDL-C?
Current evidence from 28 studies is mixed, with a slight majority of studies favoring HDL-C over apoA-I as a superior predictor of ischemic heart disease and myocardial infarction.
Evidence remains inconclusive on apoA-I versus HDL-C for MI risk prediction; hypothesis-generating and requires further study.
Ischemic heart disease is the leading cause of death worldwide, accounting for approximately 11% of all deaths in 2011. Numerous studies have shown that cardiovascular risk correlates positively and powerfully with total or LDL-cholesterol (LDL-C) and correlates inversely with HDl-cholesterol (HDL-C). Much effort has spent comparing proatherogenic cholesterol markers LDL-C, non-HDL-C, apoB and LDL particle number, while little effort has been spent comparing the markers of the antiatherogenic marker apoA-I and HDL-C. Therefore, this review focused on comparing apoA-I and HDL-C in the prediction of heart disease and myocardial infarction. We identified 28 studies of which 12 indicated that the HDL-C was likely to be a superior marker of risk for heart disease and myocardial infarction compared with eight studies that identified apoA-I to be a superior marker of risk.
No takes yet. Share an insight, caveat, or question.
Schmidt et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: